West on Lung Cancer

+ Add to Email Alerts
- 'Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC
- Unless It Improves Survival, More Is Not Better
- For NSCLC, Neoadjuvant, Adjuvant, or Both?
- Jack West and Julia Rotow Discuss ADAURA Trial Takeaways
- Did an Unfair System Help ADAURA Win on Overall Survival?
10
- The Upside of Rejection
- When Practice-Changing Results Don't Change Practice
4
- Local Therapies Show Promise for Metastatic Lung Cancer
- The Fix We Need to Break the Impasse in Precision Oncology
3
- Discontinuing Immunotherapy: Half Empty or Half Full?
1
- Discerning Bias in Cancer News
- How Would You Treat Your Spouse? Practical but Not Hard Evidence
- We Are Rebranding Suboptimal Care as Real-World Practice
13
- Live Meetings: Is the Juice Still Worth the Squeeze?
5
- Why Is Adhering to Standard of Care So Elusive?
3
- Twitter Polls: Tapping Into the Wisdom of Crowds
- Is a PFS Benefit Alone Really Worth $10,000 a Month?
4
- Swinging for the Fences: Curing NSCLC
1
- Too Soon to Utter the Word 'Cure' in Advanced Lung Cancer?
1
- When Phase 3 Data Can't Guide Oncology Decision-Making